
Goal to end AIDS by 2030 ‘more off-track' after Trump cuts, UNAIDS head says
Donald Trump's cuts to HIV/AIDS programmes will further derail an already faltering plan to end the disease as a public health threat by 2030, UNAIDS Executive Director Winnie Byanyima said on Friday, June 13, 2025.
With 1.3 million new infections in 2023, according to the latest data, the world was already 'off track,' Ms. Byanyima told journalists in South Africa, a country with the world's largest number of people living with HIV, at 8 million.
'Less funding means we will get more and more off-track,' she said in the main city of Johannesburg, after meeting President Cyril Ramaphosa to discuss Africa's HIV/AIDS strategy in light of the U.S. president slashing billions of dollars in foreign aid in February.
'We don't know yet what that impact will be, but impact there will be: ... already you see in several countries a drop in the number of people going to clinics,' Ms. Byanyima said.
Before the cuts, prevention programmes had brought down new infections, she said, but they were "not coming down fast enough to reach our target of 2023."
Now, with the shuttering of community prevention clinics across Africa, infections would surely rise, though it wasn't clear yet by how much, she said.
The administration's decision to axe swaths of U.S. foreign aid has disrupted the supply of life-saving HIV treatments, with some countries facing potentially running out. In South Africa, about a fifth of whose HIV budget was U.S.-funded, testing and monitoring of HIV patients is already falling.
Ms. Byanyima said even poor, indebted countries were managing to plug funding gaps, but called on other rich nations to step in.
'We're saying to the donors: this is one of the diseases ... without a cure, without a vaccine, yet we're seeing progress,' she said. 'If you've got a good success story, why drop it ... before you end it?'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Hindu
5 hours ago
- The Hindu
Many private hospitals in T.N. hit by acute shortage of Hepatitis B vaccine
: Private hospitals across the State have been facing a shortage of Hepatitis B vaccine over the past few months. The fall in supplies has made it difficult for many hospitals to vaccinate adults at risk, especially those on dialysis. Hepatitis B vaccine is recommended for infants under the Universal Immunisation Programme (UIP), and for adults at risk such as healthcare providers and people with compromised immune systems. Inquiries with doctors in a number of districts, including Madurai, Tiruchi, Chennai, Erode, and Theni, revealed that there is a shortage of vaccines in many private centres. A doctor in Madurai said, 'We had reached a point where we were left with very few doses of the vaccine. We could not vaccinate newborn children, but got support from government facilities. We received a supply recently, but the quantity does not meet our demand. There has been an acute shortage of the vaccine for the last seven to eight months, and we are unsure of the reason. We have been continuously raising the issue with the manufacturer almost every week.' Multi-dose vials, which have 10 doses each, are used for healthcare workers since it is cost-effective, whereas, single dose vials are used for patients, she said. 'This is mainly recommended for patients visiting nephrology and oncology departments. Due to acute shortage for a few months, we could not vaccinate them,' she added. Doctors in Erode pointed out the difficulty in vaccinating healthcare workers and patients on dialysis due to limited stock, as well as the increase in the cost of vaccines. A year ago, the Chennai Liver Foundation wrote to the vaccine manufacturing company on the poor supply of vaccines. A little later, vaccines were supplied, prioritising the pentavalent ones meant for UIP, while those for adult usage trickled in now and then, according to Vivekanandan Shanmugam, its managing trustee. 'We wrote to the Government of India and they, in response, acknowledged the short supply. They said vaccines would be supplied prioritising the pentavalent doses, and those for the high-risk population. We are not sure when this issue will be sorted out,' he said. Survey to check availability There is a real shortage, and that is why the foundation has sent a survey form to all practitioners and gastroenterologists across India to assess the availability of the vaccine in their centres, Dr. Vivekanandan says, adding: 'This is a gross problem as vaccination is crucial to prevent liver cancers. The World Health Organisation recommends Hepatitis B testing and vaccination for all adults. But given the situation, we should try to test and vaccinate at least those at high risk such as healthcare workers, child-bearing women considering the risk of transmission from mother to child, immune-compromised persons, and those with co-infections such as HIV.' A government doctor said there was increased dependency on the government sector as private hospitals in tier-2 cities and semi-urban areas were facing the shortage of vaccines. Another government doctor added that while the vaccine was freely available for the UIP, they were using the buffer stock for vaccinating patients such as those on dialysis. T.S. Selvavinayagam, Director of Public Health and Preventive Medicine, said the government sector faced no challenges with procuring the vaccine. 'We have 6.34 lakh doses. This is mainly for healthcare workers. Considering our monthly requirement of around 81,000 doses, this stock will last seven to eight months. We also have 2.62 lakh doses of pentavalent vaccine, which is part of the UIP. The pentavalent contains Hepatitis B, and we have supplies that will last over 1.5 months,' he said. He added that if there was any issue with the availability of vaccines in the private sector, people could reach out to Primary Health Centres, where vaccination would be provided as per the UIP schedule for free.


Hindustan Times
13 hours ago
- Hindustan Times
Why India needs inclusive blood donation policies now
Every year, thousands of Indians in critical medical need depend on life-saving blood transfusions. Yet, even as blood shortages persist, the country continues to enforce exclusionary policies that bar entire groups—particularly individuals from LGBTQIA+ communities and sex workers—from donating blood. These outdated bans are not just unscientific; they are discriminatory, rooted in stigma rather than evidence. It's time India reform its blood donation laws to reflect both medical advancements and human rights. India's blood donation guidelines, modeled after policies formed in the early days of the HIV/AIDS epidemic, impose blanket bans on certain populations. Men who have sex with men (MSM), trans persons, and sex workers are automatically disqualified, regardless of their individual sexual behavior, health status, or willingness to undergo testing. These guidelines paint entire communities with the same brush and are based on the assumption that persons from these communities indulge in unsafe sexual practices. Not only is this rooted in regressive moralistic codes, but it also takes the focus away from safe-sex, plurality of desire, and sexual health. Another key issue is the sidelining of advances in screening technologies and global best practices that enable safe blood collection from all individuals—regardless of identity. Modern blood banks use nucleic acid testing (NAT), which can detect HIV and other infections within days of exposure. NAT is revolutionising blood safety by detecting infections earlier than traditional serology-based tests. Unlike conventional methods, which may take weeks to detect infections, NAT identifies viral DNA or RNA within days of exposure, significantly reducing the risk of TTIs. For thalassemia patients, who undergo repeated transfusions, NAT can mean the difference between life-saving care and life-threatening complications. Excluding people based on identity rather than scientific risk factors not only violates their fundamental right to equality but also deprives the health system of potential donors. It perpetuates the harmful myth that LGBTQIA+ individuals and sex workers are inherently dangerous, further entrenching social stigma and institutional discrimination. India must urgently reform its blood donation guidelines in line with international scientific evidence and human rights norms. This begins by replacing identity-based deferrals with behavior-based screening protocols. All donors—regardless of sexual orientation, gender identity, or profession—should be assessed equally based on recent activities that may pose risk. The path forward requires a coordinated, multi-stakeholder strategy: India is at a crossroads. We can continue to let fear and misinformation dictate public health policy—or we can lead with science and compassion. We need a comprehensive review of India's blood donor eligibility criteria. This review must include consultations with medical experts, human rights advocates, and affected communities. India deserves a blood donation policy that reflects the values of equality, dignity, and modern science. This article is authored by Anubha Taneja Mukherjee, member secretary, Thalassemia Patients Advocacy Group and Rituparna Borah, co-founder and executive director, Nazariya Queer Feminist Resource Group.


The Hindu
14 hours ago
- The Hindu
Goal to end AIDS by 2030 ‘more off-track' after Trump cuts, UNAIDS head says
Donald Trump's cuts to HIV/AIDS programmes will further derail an already faltering plan to end the disease as a public health threat by 2030, UNAIDS Executive Director Winnie Byanyima said on Friday, June 13, 2025. With 1.3 million new infections in 2023, according to the latest data, the world was already 'off track,' Ms. Byanyima told journalists in South Africa, a country with the world's largest number of people living with HIV, at 8 million. 'Less funding means we will get more and more off-track,' she said in the main city of Johannesburg, after meeting President Cyril Ramaphosa to discuss Africa's HIV/AIDS strategy in light of the U.S. president slashing billions of dollars in foreign aid in February. 'We don't know yet what that impact will be, but impact there will be: ... already you see in several countries a drop in the number of people going to clinics,' Ms. Byanyima said. Before the cuts, prevention programmes had brought down new infections, she said, but they were "not coming down fast enough to reach our target of 2023." Now, with the shuttering of community prevention clinics across Africa, infections would surely rise, though it wasn't clear yet by how much, she said. The administration's decision to axe swaths of U.S. foreign aid has disrupted the supply of life-saving HIV treatments, with some countries facing potentially running out. In South Africa, about a fifth of whose HIV budget was U.S.-funded, testing and monitoring of HIV patients is already falling. Ms. Byanyima said even poor, indebted countries were managing to plug funding gaps, but called on other rich nations to step in. 'We're saying to the donors: this is one of the diseases ... without a cure, without a vaccine, yet we're seeing progress,' she said. 'If you've got a good success story, why drop it ... before you end it?'